Merck KGaA (OTCMKTS:MKKGY) Stock Now Rated “Reduce” by Wall Street Brokerages

Shares of Merck KGaA (OTCMKTS:MKKGY) have received an average recommendation of “Reduce” from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company.

MKKGY has been the subject of a number of research reports. HSBC upgraded Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Zacks Research cut Merck KGaA from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Finally, UBS Group lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th.

Merck KGaA Trading Down 2.5%

Shares of Merck KGaA stock opened at $32.08 on Friday. The firm’s 50 day moving average is $31.42 and its 200 day moving average is $30.61. The firm has a market capitalization of $20.73 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 3.11 and a beta of 0.95. Merck KGaA has a 1 year low of $23.73 and a 1 year high of $34.19. The company has a current ratio of 1.69, a quick ratio of 1.09 and a debt-to-equity ratio of 0.37.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company is separate from Merck & Co, Inc, the U.S.-based pharmaceutical company, and operates as EMD in the United States and Canada.

Merck KGaA conducts its operations through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing technologies and services used by pharmaceutical, biotechnology, academic and industrial customers.